Robertet Valuation

Is RBT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RBT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RBT (€870) is trading below our estimate of fair value (€1034.94)

Significantly Below Fair Value: RBT is trading below fair value, but not by a significant amount.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for RBT?

Key metric: As RBT is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RBT. This is calculated by dividing RBT's market cap by their current earnings.
What is RBT's PE Ratio?
PE Ratio21x
Earnings€86.35m
Market Cap€1.81b

Price to Earnings Ratio vs Peers

How does RBT's PE Ratio compare to its peers?

The above table shows the PE ratio for RBT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31.3x
AKE Arkema
16.9x20.6%€5.8b
ALBKK Baikowski
91.1xn/a€60.9m
VCT Vicat
6.1x2.3%€1.6b
VRLA Verallia Société Anonyme
10.9x10.5%€3.1b
RBT Robertet
21x8.0%€1.8b

Price-To-Earnings vs Peers: RBT is good value based on its Price-To-Earnings Ratio (21x) compared to the peer average (31.3x).


Price to Earnings Ratio vs Industry

How does RBT's PE Ratio compare vs other companies in the European Chemicals Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
RBT 21.0xIndustry Avg. 17.1xNo. of Companies11PE01224364860+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RBT is expensive based on its Price-To-Earnings Ratio (21x) compared to the European Chemicals industry average (17.9x).


Price to Earnings Ratio vs Fair Ratio

What is RBT's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RBT PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio21x
Fair PE Ratio10.8x

Price-To-Earnings vs Fair Ratio: RBT is expensive based on its Price-To-Earnings Ratio (21x) compared to the estimated Fair Price-To-Earnings Ratio (10.8x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RBT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€870.00
€1,096.67
+26.1%
4.1%€1,150.00€1,040.00n/a3
Nov ’25€933.00
€1,096.67
+17.5%
4.1%€1,150.00€1,040.00n/a3
Oct ’25€935.00
€1,096.67
+17.3%
4.1%€1,150.00€1,040.00n/a3
Sep ’25€886.00
€1,096.67
+23.8%
4.1%€1,150.00€1,040.00n/a3
Aug ’25€837.00
€1,125.00
+34.4%
2.2%€1,150.00€1,100.00n/a2
Jul ’25€823.00
€1,115.00
+35.5%
1.3%€1,130.00€1,100.00n/a2
Jun ’25€874.00
€1,115.00
+27.6%
1.3%€1,130.00€1,100.00n/a2
May ’25€882.00
€1,115.00
+26.4%
1.3%€1,130.00€1,100.00n/a2
Apr ’25€798.00
€1,040.00
+30.3%
3.8%€1,080.00€1,000.00n/a2
Mar ’25€785.00
€1,040.00
+32.5%
3.8%€1,080.00€1,000.00n/a2
Feb ’25€828.00
€1,035.00
+25.0%
3.4%€1,070.00€1,000.00n/a2
Jan ’25€830.00
€1,035.00
+24.7%
3.4%€1,070.00€1,000.00n/a2
Dec ’24€755.00
€1,035.00
+37.1%
3.4%€1,070.00€1,000.00n/a2
Nov ’24€780.00
€1,106.67
+41.9%
9.5%€1,250.00€1,000.00€933.003
Oct ’24€807.00
€1,160.00
+43.7%
7.8%€1,250.00€1,070.00€935.002
Sep ’24€847.00
€1,165.00
+37.5%
7.3%€1,250.00€1,080.00€886.002
Aug ’24€822.00
€1,165.00
+41.7%
7.3%€1,250.00€1,080.00€837.002
Jul ’24€834.00
€1,165.00
+39.7%
7.3%€1,250.00€1,080.00€823.002
Jun ’24€841.00
€1,165.00
+38.5%
7.3%€1,250.00€1,080.00€874.002
May ’24€869.00
€1,165.00
+34.1%
7.3%€1,250.00€1,080.00€882.002
Apr ’24€878.00
€1,165.00
+32.7%
7.3%€1,250.00€1,080.00€798.002
Mar ’24€914.00
€1,175.00
+28.6%
6.4%€1,250.00€1,100.00€785.002
Feb ’24€864.00
€1,150.00
+33.1%
8.7%€1,250.00€1,050.00€828.002
Jan ’24€837.00
€1,150.00
+37.4%
8.7%€1,250.00€1,050.00€830.002
Dec ’23€832.00
€1,150.00
+38.2%
8.7%€1,250.00€1,050.00€755.002
Nov ’23€845.00
€1,150.00
+36.1%
8.7%€1,250.00€1,050.00€780.002

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies